S-1/A: Kairos Pharma Eyes NYSE American Listing with $6.2 Million IPO

Kairos Pharma, a clinical-stage biopharmaceutical company, is seeking to raise $6.2 million through an initial public offering to advance its cancer therapeutics pipeline and list its stock on the NYSE American under the symbol KAPA.

Summary

• Kairos Pharma, a clinical-stage biopharmaceutical company, has filed an amendment to its Form S-1 registration statement for a proposed initial public offering.
• The company plans to offer 1,550,000 shares of its common stock at an expected initial public offering price of $4.00 per share, aiming to raise $6.2 million.
• Kairos Pharma is seeking to list its common stock on the NYSE American LLC under the ticker symbol KAPA.
• The company intends to use the net proceeds from the offering to fund Phase 1 and Phase 2 clinical trials of its product candidates, including ENV 105 and preclinical product candidates including KROS 101, potential acquisition or in-licensing activities, and for working capital and general corporate purposes.
• The underwriters have a 45-day option to purchase up to an additional 232,500 shares of common stock to cover over-allotments.
• Boustead Securities, LLC and EF Hutton LLC are acting as underwriters for the offering.
• The company's pipeline includes seven drug candidates targeting various cancers, including prostate cancer, lung cancer, breast cancer, and glioblastoma.
• Kairos Pharma has licensed key patents from Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc.
• The company is an emerging growth company and a smaller reporting company, which allows it to take advantage of certain exemptions from various public company reporting requirements.
• As of June 3, 2024, the company had three part-time employees and conducts its operations virtually.

Sentiment

Score: 6

Explanation: The document presents a balanced view of the company, highlighting both its potential and the risks associated with investing in it. The company has a promising pipeline and is targeting large markets, but it also faces significant challenges, including a limited operating history, significant losses, and the need for additional funding.

Positives

• The company has a diversified pipeline of seven drug candidates.
• The company has licensed key patents from Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc.
• The company is an emerging growth company and a smaller reporting company, which allows it to take advantage of certain exemptions from various public company reporting requirements.
• The National Cancer Institute / National Institutes of Health (NIH) was awarding Neil Bhowmick, PhD, our Chief Scientific Officer and also a Cedars-Sinai Professor of Medicine, a grant of $3.2 million to support the development of the mechanism of action and companion biomarkers in research that is being performed by Cedars-Sinai in conjunction with our ongoing Phase 2 trial for ENV105 (carotuximab) and apalutamide treating castrate resistant prostate cancer patients.

Negatives

• The company has incurred significant losses since its inception and expects to continue to incur losses for the foreseeable future.
• The company has limited operating history and no products approved for commercial sale.
• The company is relying exclusively on the skills and expertise of its management team, not all of whom will devote all of their time to managing the Company, and the company currently has no full-time employees, which may impede its ability to carry on its business.
• The company has identified material weaknesses in its internal control over financial reporting.
• The report of the company's independent registered public accounting firm included a going concern explanatory paragraph.

Risks

• The company requires substantial additional funding to meet its financial needs and to pursue its business objectives.
• The company faces substantial competition from large, well-funded, and experienced competitors.
• The company's exclusive licensing rights to its intellectual property are subject to agreements with third parties and the company may not meet milestones set forth in those agreements or its exclusive licensing rights may be terminated.
• The company has limited experience designing and implementing clinical trials and has never conducted pivotal clinical trials.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable.
• The trading price of the company's common stock may be volatile, and investors could lose all or part of their investment.

Future Outlook

The company expects to continue to incur significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through clinical development, seeks regulatory approval, and operates as a public company.

Industry Context

The announcement is taking place within the context of a rapidly growing immuno-oncology market, with global cancer drug spending expected to reach $311.2 billion by 2026. The company is positioning itself to compete in this market by developing novel therapeutics that address key challenges in cancer treatment, such as drug resistance and immune suppression.

Comparison to Industry Standards

• The company's lead drug candidate, ENV 105, is being developed to address resistance to androgen-targeted therapy in prostate cancer, a market where androgen signaling inhibitors generate $10 billion in annual sales.
• The company is also targeting EGFR-mutant non-small cell lung cancer, a market where Tagrisso (osimertinib, AstraZeneca) generates $3 billion in annual sales.
• The company's KROS 201 activated T cell therapy is targeting glioblastoma, a market where T cell therapy is expected to reach $20.8 billion by 2030.
• The company's KROS 101 and KROS 102 checkpoint inhibitors are targeting a market that is expected to reach $148 billion by 2029.
• The company's ENV 205 is targeting cachexia, a market that is estimated to reach above $1 billion in the U.S. alone.

Related Party Transactions

• Shareholders of the Company, and a company whose principal stockholder is also a stockholder of the Company, advanced the Company $0.01 million, which was all outstanding at December 31, 2021.
• Two officers and shareholders agreed to convert the $0.004 million due to them into 1,664 shares of the Companys common stock, effective upon the closing of the Companys IPO.
• Subsequent to December 31, 2023, the Company borrowed $0.07 million from three of its officers.
• Subsequent to December 31, 2023, the Company borrowed $0.03 million from two of its officers.

Stakeholder Impact

• Shareholders will be diluted by the issuance of new shares in the offering.
• Employees may benefit from the company's growth and success.
• Patients may benefit from the development of new cancer therapeutics.
• Customers (potential pharmaceutical partners) may benefit from access to the company's innovative technologies.
• Suppliers and creditors may benefit from the company's increased financial stability.

Next Steps

• Complete the initial public offering and list its stock on the NYSE American.
• Advance its product candidates through preclinical and clinical development.
• Seek regulatory approval for its product candidates.
• Potentially acquire or in-license additional product candidates.
• Continue to build its team and infrastructure.

Key Dates

Keywords

Kairos Pharma, IPO, biopharmaceutical, cancer therapeutics, ENV 105, KROS 101, clinical trials, NYSE American, drug resistance, immune suppression